Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Markers Shift Focus To Local Generics Market

This article was originally published in PharmAsia News

Executive Summary

Indian drug makers that once focused on selling generic versions of best-selling drugs abroad are now looking to their home country for profits. The tactic has raised Cipla to the dominate position in India along with Ranbaxy Laboratories, ahead of GlaxoSmithKline, a multinational that led as recently as 2006. Companies turning their attention towards their domestic market have been building strength in those operations. They also continue to fight for adding to their share of the global market, but domestic competition now is just as strong. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts